Press release
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022.\n\nIn connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 3, 2022, to discuss the Company’s financial results and provide a corporate update.\n\nConference ID: 2791984\nDomestic Dial-in Number: (833) 646-0603\nInternational Dial-in Number: (929) 517-9782\nLive Webcast: https://edge.media-server.com/mmc/p/ci4evdm2\n\nA replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.\n\nAbout Gossamer Bio\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220228005298/en/\n\nFor Investors and Media:\nBryan Giraudo, Chief Financial Officer & Chief Operating Officer\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3138,"tagName":"div"}]